BERGENBIO COVID-19 DATA PRESENTED AT THE ANNUAL AMERICAN SOCIETY FOR VIROLOGY
Bergen, Norway, 21 July 2021 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that pre-clinical data evaluating bemcentinib, BerGenBio’s first-in-class, potent and highly selective AXL inhibitor, for the treatment of SARS-CoV-2 infection has been presented at the 40[th] Annual American Society for Virology (ASV). The presentation was given by BerGenBio’s collaborator, Mr. Dana Bohan, a PhD candidate from the University of Iowa, who outlined previously announced